// ISI component
table(width=max_w align="center" class="mobile-table")&attributes(tableAtt)
  tr
    td
      table(bgcolor="#1E1C1C")&attributes(tableAtt)
        tr
          +hSpacer(127)
          td(width="318" bgcolor=bright_orange align="center" class="mobile-table")
            table&attributes(tableAtt)
              +vSpacer(6)
              tr
                td
                  table&attributes(tableAtt)
                    tr
                      td
                        font(color="#ffffff" style="font-family: Arial,sans-serif; color: #ffffff; font-size: 16px;")
                          a(style="text-decoration:underline;") Learn about the selectivity of abaloparatide
              +vSpacer(6)
          +hSpacer(155)
  tr(bgcolor="#1E1C1C" class="mobile-hide")
    td
      table&attributes(tableAtt)
        tr
          +hSpacer(25)
          td
            table&attributes(tableAtt)
              +vSpacer(35)
              tr
                td
                  font(style="font-size:13px;" color=bright_orange) 
                    strong  IMPORTANT SAFETY INFORMATION (cont'd)
              +vSpacer(20)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;")
                    strong(style="color:"+bright_orange+";") Orthostatic Hypotension: 
                    |   Orthostatic hypotension may occur with TYMLOS, typically within 4&nbsp;hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.  
              +vSpacer(15)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;")
                    strong(style="color:"+bright_orange+";") Hypercalcemia: 
                    |   TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.
              +vSpacer(15)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;")
                    strong(style="color:"+bright_orange+";") Hypercalciuria and Urolithiasis: 
                    |   TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.
              +vSpacer(15)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;")
                    strong(style="color:"+bright_orange+";") Adverse Reactions: 
                    |   The most common adverse reactions (incidence ≥2%) are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.
              +vSpacer(35)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;") Please see 
                    a(style=`color:${bright_orange};text-decoration:underline;font-weight:bold;`) Important Safety Information
                    |   and 
                    a(style=`color:${bright_orange};text-decoration:underline;font-weight:bold;`) Full Prescribing Information
                    | , including&nbsp;Boxed&nbsp;Warning, at 
                    a(style=`color:${bright_orange};text-decoration:underline;font-weight:bold;`) TYMLOShcp.com
                    |.
              +vSpacer(35)
              tr
                td
                  font(color=bright_orange style="font-size:14px;") Study Design
              +vSpacer(20)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;") A randomized, multicenter, double-blind, placebo- and active-controlled clinical study in postmenopausal women with osteoporosis aged 49 to 86 years (mean age 69 years) who were randomized to receive 80 mcg of TYMLOS (n=824) or placebo (n=821), given subcutaneously once daily for 18 months.#[sup 1,3]
              +vSpacer(20)
              tr
                td
                  font(color="#ffffff" style="font-size:10px;") 
                    strong  References: 1. 
                    |   TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 
                    strong  2. 
                    |   Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314-319. 
                    strong  3. 
                    |   Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-733. [Erratum: JAMA. 2017;317(4):442.] 
                    strong  4. 
                    |   Pola E, Pambianco V, Colangelo D, Formica VM, Autore G, Nasto LA. Teriparatide anabolic therapy as potential treatment of type II dens non-union fractures. World J Orthop. 2017;8(1):82-86. 
                    strong  5. 
                    |   Data on File. Medi-Span; price Rx. July 2017. 
                    strong  6. 
                    |   Forteo® [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2017.
              +vSpacer(35)
          +hSpacer(15)
          
  tr(style="display:none;" bgcolor="#1E1C1C" class="mobile-show")
    td
      table&attributes(tableAtt)
        tr
          +hSpacer(10)
          td
            table&attributes(tableAtt)
              +vSpacer(35)
              tr
                td
                  font(style="font-size:13px;" color=bright_orange) 
                    strong  IMPORTANT SAFETY INFORMATION (cont'd)
              +vSpacer(20)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;")
                    strong(style="color:"+bright_orange+";") Orthostatic Hypotension: 
                    |   Orthostatic hypotension may occur with TYMLOS, typically within 4&nbsp;hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.  
              +vSpacer(15)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;")
                    strong(style="color:"+bright_orange+";") Hypercalcemia: 
                    |   TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.
              +vSpacer(15)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;")
                    strong(style="color:"+bright_orange+";") Hypercalciuria and Urolithiasis: 
                    |   TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.
              +vSpacer(15)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;")
                    strong(style="color:"+bright_orange+";") Adverse Reactions: 
                    |   The most common adverse reactions (incidence ≥2%) are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.
              +vSpacer(35)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;") Please see 
                    a(style=`color:${bright_orange};text-decoration:underline;font-weight:bold;`) Important Safety Information
                    |   and 
                    a(style=`color:${bright_orange};text-decoration:underline;font-weight:bold;`) Full Prescribing Information
                    | , including&nbsp;Boxed&nbsp;Warning, at 
                    a(style=`color:${bright_orange};text-decoration:underline;font-weight:bold;`) TYMLOShcp.com
                    |.
              +vSpacer(35)
              tr
                td
                  font(color=bright_orange style="font-size:14px;") Study Design
              +vSpacer(20)
              tr
                td
                  font(color="#ffffff" style="font-size:13px;") A randomized, multicenter, double-blind, placebo- and active-controlled clinical study in postmenopausal women with osteoporosis aged 49 to 86 years (mean age 69 years) who were randomized to receive 80 mcg of TYMLOS (n=824) or placebo (n=821), given subcutaneously once daily for 18 months.#[sup 1,3]
              +vSpacer(20)
              tr
                td
                  font(color="#ffffff" style="font-size:10px;") 
                    strong  References: 1. 
                    |   TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 
                    strong  2. 
                    |   Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314-319. 
                    strong  3. 
                    |   Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-733. [Erratum: JAMA. 2017;317(4):442.] 
                    strong  4. 
                    |   Pola E, Pambianco V, Colangelo D, Formica VM, Autore G, Nasto LA. Teriparatide anabolic therapy as potential treatment of type II dens non-union fractures. World J Orthop. 2017;8(1):82-86. 
                    strong  5. 
                    |   Data on File. Medi-Span; price Rx. July 2017. 
                    strong  6. 
                    |   Forteo® [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2017.
              +vSpacer(35)
          +hSpacer(10)
